We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

Feel our pain

1 October 2004 By Robert Cyran

The withdrawal of the US group s arthritis drug will cause knockon effects throughout the drug sector. Merck will promote its remaining drugs heavily. Novartis and Glaxo will find life tougher. But ScheringPlough could be a beneficiary.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)